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cancer shows the effectiveness and the absence of excess 
toxicity (above the level II) after the CRT with accelerated 
fractionation dose in CBT. It is assumed to analyze the 
dynamics of accumulation of cytogenetic markers in PBL and 
their deviation from the normal distribution in the course and 
after the CRT of cancer patients. 
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Purpose/Objective: Adaptive radiotherapy approaches for 
cervical cancer patients can have different levels of update 
frequency, varying between re-planning halfway along the 
treatment, weekly re-planning and plan of the day 
approaches. We investigated the variation in organ shape 
within a treatment week and the exemplarity of different 
adaptive strategies.  
Materials and Methods: For 8 cervical cancer patients we 
obtained weekly CT scans and daily CBCT scans. The primary 
and nodal GTVs, bladder, rectum, sigmoid, bowelbag were 
delineated in all 215 scans by a radiation oncologist. Six 
patients were classified as mover (>2.5 cm top of uterus 
motion), two as non-mover. In order to assess the 
appropriateness of different adapted PTV concepts, the 
volume of the cervix-uterus CTV that exceed those PTVs was 
calculated for a static PTV based on planning scan, a weekly 
update of the PTV based on weekly CT scan, a PTV of the CT 
scan with a similar bladder filling status, and based on a plan 
of the day (PotD) approach that consists of an empty – half 
full PTV and a half full – full PTV.  
Results: For the commonly used planning strategy that uses 
one planning CT scan with arbitrary bladder volume, up to 
40% of the daily CTV can be outside the PTV during one or 
more fractions of the treatment; for movers with a large 
bladder filling variation, on average 20-25%. Adaptation of 
the PTV by re-planning on a weekly CT scan, or re-planning 
based on a CT scan with similar bladder volume, decreased 
the volume of the daily CTV outside the PTV somewhat 
(Figure). Besides bladder filling also the status of the rectum 
influenced the position. A PTV created with a PotD approach, 
resulted in acceptable small volumes outside the PTV 
(average 2%). For three mover patients the uterus flipped 
backwards for a few days during treatment and a non-mover 
changed into a mover for a few fractions.  
 
Conclusions: We found that re-planning based on weekly 
imaging, although this gives a good idea about organ position 
variability and tumor shrinkage, is not sufficient to reflect 
the full extent of internal organ motion because the patient 
changes daily and often weekly scans are not made at the 
same time point (and organ configuration) as the treatment 
fraction itself. Furthermore, bladder volume-dependent 
cervix-uterus motion models that were prepared in the 
planning phase should be monitored carefully throughout the 
treatment because they can change.  
   
PO-0756   
Carbon-ion and photon radiation effects on HPVñpositive 
and negative cervical carcinoma cells 
K. Lindel1, M. Vercruysse1, S. Rieken1, S. Daffinger1, K.J. 
Weber1, J. Debus1 
1University Hospital Heidelberg, Radiation Oncology, 
Heidelberg, Germany  
 
Purpose/Objective: To compare the effect of photon and 
carbon-ion radiation on four cell lines with different HPV-
status regarding cell cycle regulation and HPV associated 
protein expression. Hypothesis is that carbon ion radiation 
might overcome radiation resistance of HPV-negative cells or 
cells with integrated HPV. 
Materials and Methods: W12 cell line was derived from a low 
grade cervical lesion by Stanley MA et al. 1989, and is unique 
among HPV16-containing cell lines in carrying its HPV 16 
genome as a multicopy episome. W12 cells contain episomal 
HPV 16 genomes, whereas S12 cells, which derived from the 
W12 line, contain HPV DNA as integrated copies. Caski cells 
have their origin in epidermoid cell cervical cancer and are 
reported to contain an HPV 16 genome as well as sequences 
related to HPV-18. C33A is a HPV-negative human cervical 
cancer derived cell line. Cell cycle analyses were performed 
using flow cytometry (PI staining) 24 h and 48 h after RT with 
2 and 7 Gy using photon RT and 2 GyE and 7 GyE carbon ion 
RT(C12). Expression of pRb and p53 after irradiation with 2 
and 7 Gy were analyzed by flow cytometry using intracellular 
staining comparing the mean fluorescence of 10000 gated 
cells. 
Results: C33A cells (HPV-negative) showed a minimal 
enhanced expression of pRB after RT with photons or C12 (0 
Gy=1.0, 2 Gy=1.09, 7 Gy=1. 4, 2 GyE= 1.3, 7 GyE=1.1). There 
was no effect of photon or C12 irradiation on p53 expression 
in C33A cells. Caski cells (HPV16/18 positive) showed 
increased expression of pRb after photon RT (2 Gy=1.3, 7 
3rd ESTRO Forum 2015                                                                                                                                         S375 
 
Gy=1.7). Irradiation with C12 induced a strong increase of 
pRb expression (2 GyE=7.7, 7 GyE=8.3). There was a minimal 
change of p53 expression after RT (2 Gy=1.3; 7 Gy=1.2, 2 
GyE=1.6, 7 GyE=1.5). S12 cells (HPV 16 integrated) showed a 
decrease of pRB expression after RT with photons (2 Gy=0.47, 
7 Gy=0.38). Irradiation with C12 enhanced the expression of 
pRb positive cells (2 GyE= 1.8,7 GyE=1.94), but showed no 
significant expression of p53 in the control group. W12 cells 
(HPV 16 episomal) showed no change of pRb expression in the 
control group or after RT. C12 RT induced an increase of pRb 
expression (2 GyE=1.5, 7 Gy=2.9). There was no significant 
change of p53 expression in W12 and S12 cells after RT. C12-
RT showed no effect on cell cycle distribution in W12/S12 
and C33A cells. 48 h after irradiation with 7 Gy photons in 
C33A cells and 24 h after RT in S12 cells a G2/M-block was 
induced. 
Conclusions: The effect of carbon-ion-RT on protein 
expression seems to be dependent on HPV-status and type of 
protein with no effect on p53 or on HPV-negative cells, but a 
strong effect on pRb expression in HPV-positive cells. The 
converse effect of carbon-ion-RT compared to photon-RT on 
HPV positive cell with integrated HPV regarding pRb 
expression indicates that carbon-ion therapy might overcome 
HPV-integration induced radioresistance. 
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Purpose/Objective: Chemoradiation followed by a 
brachytherapeutic boost is standard of care for locally 
advanced cervical cancer (LACC). In the past, we 
implemented safely the use of neo-adjuvant chemoradiation 
using arc therapy. This allowed for a safe completion 
hysterectomy. This is a report on the long-term outcome 
results of this approach.  
Materials and Methods: Fifty-nine patients with LACC were 
treated (Figo IB: n=6; II: n= 41; III: n= 9; IV: n=3) between 
12/2005 and 08/2014. Chemotherapy, administered in 51 
patients (86%), consisted of weekly cisplatin (40mg/m2). 
Radiation consisted of an Intensity Modulated Arc Therapy 
delivered in 25 fractions. No neo-adjuvant brachytherapeutic 
treatment was performed. Dose prescription was: 62 Gy and 
60 Gy (Dmed) to the primary tumour and PET/CT-positive 
lymph nodes respectively; 45 Gy (minimal dose) to the 
uterus, cervix, upper vaginal 1/3 to ½, parametria and pelvic 
lymph nodes. Para-aortic irradiation was performed if N+ 
(n=22 or 37%). 
Six weeks after the neo-adjuvant chemoradiation a 
hysterectomy was performed. Suspected lymph nodes at the 
start of the treatment were resected selectively.  
Radiotherapeutic and surgical feasibility and the low 
morbidity/toxicity rates have been published before. 
Results: Median FU is 33 months (3-101m). Median age at 
diagnosis was 56y (21-89). Pathologic complete response rate 
is 36% (ypT0: 36%; ypT1a: 26,4%; ypT1b: 28,8%, ypT2a1: 1,7%; 
ypT2b: 6,8%). Lymphnode resection was performed in 29 
patients of which 6 had positive nodes. Surgical margins were 
free of disease in all but 2 cases (a brachytherapeutic boost 
was performed). Two- and 5-year local control rates are 94%. 
Two patients relapsed in a pelvic lymph node (2- and 5-year 
regional control = 96%). Two- and 5-year distant metastasis 
free survival is 91%. One patient developed a lung metastasis 
67 months after primary diagnosis, after resection no 
progression was noted. Two- and 5-year disease-specific 
survival are both 94% and 88%. Two- and 5-year OS are 88% 
and 69% (4/9 death causes were not cervical cancer related).  
Conclusions: Neo-adjuvant chemoradiation using modern 
radiotherapy techniques leads to promising control and 
survival rates. Further research should be considered to 
confirm these promising data. 
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Purpose/Objective: Wilms tumor or nephroblastoma is the 
most common primary renal tumor of children, with about 
500 cases per year in the United States. Treatment is 
individualized by tumor histology, stage, and a variety of 
biologic factors that help determine a patients' risk strata, 
and may include surgery, chemotherapy, and radiation 
therapy. This study sought to evaluate the outcomes for 
patients with Wilms tumor treated at a single institution. 
Materials and Methods: A retrospective review was 
performed of all children with Wilms tumor treated at a 
single institution from January 1994 through December 2012. 
Patients were staged by the NWTS system and managed on- 
or per- COG protocols. Stage I and II patients were generally 
managed with surgery and adjuvant chemotherapy. Stage III 
patients were generally managed with surgery followed by 
adjuvant chemotherapy and flank/abdominal radiotherapy. 
Stage IV patients were most commonly managed with 
surgery, chemotherapy, and flank/lung radiotherapy. Stage V 
patients generally received only surgery and chemotherapy. 
MedCalc was utilized to develop Kaplan-Meier plots of 
progression free and overall survival for the population. 
Results: Of the 64 treated patients, there were 7 patients 
with recurrence (10.9%). There were no recurrences in 11 
patients with stage I disease.  
There were 15 patients with stage II disease of which 3 
patients (20%) experienced recurrence. Two patients 
